SCHEMBL17113448

SCHEMBL17113448

O=C1NCCN(c2ncc(-c3cccc(Nc4nccc(C(F)(F)F)n4)c3)o2)C12CC2

nearest known ligand 0.67

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 20/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17113608 0.97 SYK (0.63) SYK
SCHEMBL18627945 0.90 SYK (0.56) SYK
SCHEMBL17113586 0.89 SYK (0.58) SYK
SCHEMBL17113385 0.88 SYK (0.75) SYK
SCHEMBL17113285 0.87 SYK (0.69) SYK
SCHEMBL17113491 0.86 SYK (0.68) SYK
SCHEMBL17113442 0.85 SYK (0.67) SYK
SCHEMBL17113521 0.85 SYK (0.69) SYK
SCHEMBL17113289 0.85 SYK (0.67) SYK
SCHEMBL17113590 0.85 SYK (0.69) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3122744-B1 DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2018-11-07 — — EP claimed
US-10053455-B2 Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors AB SCIENCE (FR) 2018-08-21 — — US claimed
US-20180179195-A1 DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2018-06-28 — — US claimed
EP-3122744-A1 DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS AB Science (FR) 2017-02-01 — — EP claimed
WO-2015144614-A1 DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2015-10-01 — — WO claimed
EP-3122744-B1 DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2018-11-07 — — EP disclosed
US-10053455-B2 Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors AB SCIENCE (FR) 2018-08-21 — — US disclosed
US-20180179195-A1 DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2018-06-28 — — US disclosed
US-20180179195-A1 DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2018-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053455-B2 Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors SYK, ZAP70, LCK SYK 1/4885
US-20180179195-A1 DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS SYK, ZAP70, LCK SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback